Press release
Insmed Highlights Progress Across Portfolio and Outlines Growth Strategy at R&D Day
- Initiated Phase 1 study of treprostinil palmitil inhalation powder (TPIP); Phase 2a study in pulmonary arterial hypertension planned for 2021 - - Expects to
About this update from Insmed Incorporated
[{"type":"text","content":"- Initiated Phase 1 study of treprostinil palmitil inhalation powder (TPIP); Phase 2a study in pulmonary arterial hypertension planned for 2021 -\n - Expects to initiate registrational Phase 3 ASPEN trial of brensocatib in patients with non-cystic fibrosis bronchiectasis (NCFBE) in fourth quarter of 2020; expansion into additional neutrophil-mediated diseases planned in 2021 -\n - Expanding commercial opportunity for ARIKAYCE with planned European launch by end of 2020 and potential Japanese launch in 2021, if approved, in refractory MAC lung disease; expects to initiate registrational program in front-line NTM in 2020 -\n - Cash runway of over three years based on currently planned development programs -\n\n\nBRIDGEWATER, N.J., Sept. 30, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced progress across its portfolio of therapies and pipeline candidates, which will be discussed in further detail today at the Company's virtual Research & Development (R&D) Day. The event will feature presentations from the Insmed management team and Ronald J. Oudiz, M.D., FACP, FACC, FCCP, Professor of Medicine at the David Geffen School of Medicine at the University of California Los Angeles (UCLA), the Interim Chief, Division of Cardiology, and a Director at the Liu Center for Pulmonary Hypertension at the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, and the lead investigator in the Company's planned Phase 2a trial for treprostinil palmitil inhalation powder (TPIP). \n\"Our success in building a commercial company with a global footprint and strong pipeline sets the stage for Insmed's next chapter of growth,\" said Will Lewis, Chair and Chief Executive Officer of Insmed. \"With ARIKAYCE, our global expansion efforts and upcoming study in front-line NTM patients has the potential to establish this first-in-disease program as the standard of care in NTM lung disease worldwide. We believe brensocatib, our DPP1 inhibitor, offers an entirely new approach to address a wide array of neutrophil-mediated diseases. We plan to build upon our early leadership position in this space with our anticipated near-term registrational study in NCFBE, followed by a new development program in cystic ...